ubmslateOT-logo-ubm

OT mobile menu

Search form

Topics:

Lung Cancer Targets

Study Identifies How Lung Tumors Acquire Immunotherapy Resistance

NSCLC can acquire resistance to immune checkpoint blockade agents through evolutionary culling of tumor clones harboring the mutations for cell surface neoantigens that are recognized by patients’ immune T cells. Image © Tashatuvango/ Shutterstock.com

Image © koya979 / Shutterstock.com

Lung Cancer Targets

ERBB2/HER2 mutations appear to be rare but targetable oncogenic drivers in non-small cell lung cancer, according to findings from a small retrospective cohort records analysis.

An IHC assay for ALK status in non-small cell lung cancer tumor tissue predicts crizotinib treatment outcomes and offers a rapid and potentially less expensive alternative to older FISH ALK status assays.

A study just published in Cancer Cell is suggesting a new target for combating KRAS-mediated lung adenocarcinoma.

In my practice, I am constantly being asked how to properly treat scalp involvement in relation to these skin toxicities.

Among active or former smokers undergoing lung cancer screening, longer peripheral leukocyte telomere length is associated with an increased risk of lung cancer.

Non-small cell lung cancer can acquire resistance to immune checkpoint blockade agents through evolutionary culling of tumor clones harboring the mutations for cell surface neoantigens that are recognized by patients’ immune T cells.

A 38-year-old woman presents with multiple pulmonary nodules. After further assessment a biopsy is performed. What is your diagnosis?

Pages

Subscribe to Lung Cancer Targets on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.